Article Text

Download PDFPDF

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
  1. Walter Fiedler1,
  2. Sara Cresta2,
  3. Henning Schulze-Bergkamen3,
  4. Sara De Dosso4,
  5. Jens Weidmann1,
  6. Anna Tessari2,
  7. Hans Baumeister5,
  8. Antje Danielczyk6,
  9. Bruno Dietrich7,
  10. Steffen Goletz8,
  11. Alfredo Zurlo9,
  12. Marc Salzberg10,
  13. Cristiana Sessa4,
  14. Luca Gianni11
  1. 1 Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus-Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  2. 2 Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy
  3. 3 Department of Medical Oncology, National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany
  4. 4 Oncology Institute of Southern Switzerland, Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
  5. 5 Immunomonitoring, Glycotope GmbH, Berlin, Germany
  6. 6 R&D, Glycotope GmbH, Berlin, Germany
  7. 7 Clinical Development, Glycotope GmbH, Berlin, Germny
  8. 8 R&D, Glycotope GmbH, Berlin, Germany
  9. 9 Clinical Development, Glycotope GmbH, Berlin, Germany
  10. 10 Pharma Brains AG, Basel, Switzerland
  11. 11 Department of Medical Oncology, Ospedale San Raffaele, Milano, Italy
  1. Correspondence to Dr Walter Fiedler; fiedler{at}uke.uni-hamburg.de

Abstract

Background Changes in glycosylation of the constant domain (Fc) of monoclonal antibodies (mAbs) enhance antibody-dependent cell-mediated cytotoxicity independently of downstream effects following receptor blockade by the antibody, thus extending their indication. We investigated the safety, pharmacokinetics, pharmacodynamics and antitumour activity of tomuzotuximab, an IgG1 glycoengineered mAb against the epidermal growth factor receptor with enhanced tumour cytotoxicity in a phase I dose-escalation study (NTC01222637).

Patients and methods Forty-one patients with advanced solid tumours refractory to standard therapies received tomuzotuximab weekly (12–1370 mg) or two-weekly (990 mg) on a three-plus-three dose escalation design.

Results A maximum tolerated dose was not reached. The most frequent treatment-related adverse events were infusion-related reactions in 31 (76%) patients (grade 3, 12%), mainly confined to the first dose, and skin toxicities (grade 1 or 2) in 30 (73%) patients. Hypomagnesaemia was observed in 9 out of 23 evaluable patients (39%). Similar to cetuximab, tomuzotuximab concentrations increased proportionally to dose from doses≥480 mg with a median terminal half life (t½) of 82 hours, range 55–113 hours. Antitumour activity included one complete response ongoing since more than 4.5 years in a patient with non-small-cell lung cancer and one partial response lasting 353 days in a patient with colorectal cancer. Twelve patients achieved stable disease (median, 166 days, range, 71–414 days) and two patients had prolonged control (>1 year) of their non-measurable disease.

Conclusion Tomuzotuximab was safe and showed promising antitumour activity in heavily pretreated patients with advanced metastatic disease. A phase IIb trial of chemotherapy and weekly tomuzotuximab or cetuximab followed with maintenance therapy with the corresponding mAb in patients with recurrent or metastatic head and neck squamous cell carcinoma is ongoing.

  • tomuzotuximab
  • phase I
  • egfr
  • monoclonal antibody
  • glycoengineered

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Conception and design: WF, HB, BD, SG, AD, CS, LG. Provision of study materials or patients: WF, SC, HS-B, JW, SDD, AT, HB, BD, AD, CS, LG. Collection and assembly of data: WF, SC, HS-B, JW, SDD, AT, HB, CS, LG. Data analysis and interpretation: WF, HB, BD, AD, SG, AZ, CS, LG. Reading and approval of the final manuscript: all authors.

  • Funding This work was supported by Glycotope GmbH, which provided the drug and financial support for the conduct of the trial. The authors were fully responsible for all content and editorial decisions, were involved in all stages of manuscript preparation and have approved the final version.

  • Competing interests Employment or leadership position: HB, BD, SG, AZ, AD. Stock ownership: HB, SG, AD. MS was employee of Pharma Brains AG, which received funding for the study from Glycotope GmbH. Other remuneration: WF, Meeting participation to present the data at the American Society of Clinical Oncology 2013 Annual Meeting.

  • Patient consent Obtained.

  • Ethics approval Ethik-Kommission der Ärztekammer Hamburg and the Ethics Committees of each Center.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.